Site info hipertenzija
Diagnosis site info hipertenzija Treatment of Pulmonary Hypertension.
Source: Scripta Medica. Apr, Vol. Five groups of patients have been defined: group 1 as pulmonary arterial hypertension PAHgroup 2 as PH due to left heart disease, group 3 as Site info hipertenzija due to lung diseases, group 4 as chronic thromboembolic PH, and group 5 as PH of other causes.
The early clinical symptoms and signs site info hipertenzija subtle and non-specific, such as exertional dyspnea, fatigue, pre-syncope and progressive limitation of exercise capacity so the vast majority of patients have an advanced disease with World Site info hipertenzija Organization functional class of III or IV at first presentation.
The diagnostic approach in PH has the goal to evaluate the two main anatomic components: pulmonary vasculature and right ventricle in order to establish the diagnosis and identify the group of PH. The therapy for PAH patients includes three main components: general measures and supportive therapy; initial therapy with calcium channel blockers in vasoreactive or specific drugs approved for PAH in non-vasoreactive patients either single or in combination, and lung transplantation.
All patients with PAH should be referred to PH expert centers for comprehensive diagnostic and therapeutic assessment. Copyright of Scripta Medica is the property of Scripta Medica and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission.
However, users may print, download, or email articles for individual use.
This abstract may be abridged. No warranty is given about the accuracy of the copy.
Users should refer to the original published version of the material for the full abstract. Important User Information: Remote access to EBSCO's databases is site info hipertenzija to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use. However, remote access to EBSCO's databases from non-subscribing institutions is not allowed if the purpose of the use is for commercial gain through cost reduction or avoidance for a non-subscribing institution.